| Click on an individual's name or image to view his or her biography. |
|
|
|
Executive Management
|
|
Walter C. Herlihy
President and Chief Executive Officer
| Walter C. Herlihy, Ph.D. joined Repligen in March 1996 as President, Chief Executive Officer and Director
in connection with Repligen’s merger with Glycan Pharmaceuticals, Inc. From July 1993 to March 1996,
Mr. Herlihy was the President and CEO of Glycan Pharmaceuticals, Inc. From October 1981 to June 1993, he
held numerous research positions at Repligen, most recently as Senior Vice President, Research and
Development. Mr. Herlihy holds an A.B. in chemistry from Cornell University and a Ph.D. in chemistry from
MIT. The Board of Directors believes Mr. Herlihy’s qualifications to sit on the Board of Directors include his
decades of experience in the pharmaceutical field, including over 15 years as President and Chief Executive
Officer of the Company, and his deep understanding of the Company’s historical and current business strategies,
objectives and products. |
|
Jonathan I. Lieber
Chief Financial Officer and Treasurer
| Jonathan I. Lieber has served as our Chief Financial Officer and Treasurer since joining the Company in
September 2012. From June 2009 to May 2012, Mr. Lieber served as Chief Financial Officer and Treasurer of
Xcellerex, Inc., a privately-held company engaged in the manufacture and sale of capital equipment and related
consumables to the biopharmaceutical industry. From July 2002 to March 2009, Mr. Lieber served in a variety of
roles at Altus Pharmaceuticals, Inc. most recently as Senior Vice President, Chief Financial Officer and
Treasurer. Following Mr. Lieber’s departure, Altus Pharmaceuticals, Inc. filed a voluntary petition for
bankruptcy under Chapter 7 of the U.S. bankruptcy code in November 2009. From 1998 to June 2002, Mr. Lieber
was a member of SG Cowen’s Health Care Investment Banking Group, most recently as a vice president focused
on the biotechnology and specialty pharmaceuticals sectors. Prior to joining SG Cowen, Mr. Lieber was a
member of the Health Care and High Yield Groups at Salomon Brothers Inc. Mr. Lieber currently serves as a
member of the Atrius Health audit committee. Mr. Lieber received an M.B.A. in finance from the Stern School of
Business of New York University and a B.S. in business administration from Boston University. |
|
|
William J. Kelly
Chief Accounting Officer
| William J. Kelly joined Repligen in March 2008 as Vice President, Finance and Administration, served as
Chief Financial Officer from 2008 until September 2012 and currently serves as Chief Accounting Officer. Prior
to joining Repligen, Mr. Kelly worked for Haemonetics Corporation, a medical device manufacturer, where he
held the positions of Corporate Controller from 2005 to 2008 and Assistant Corporate Controller from 2001 to
2005. From 2000 to 2001, Mr. Kelly was Corporate Controller for SiteScape Corporation. Mr. Kelly is a
Certified Public Accountant and previously worked for Deloitte and Touche LLP, most recently as audit
manager, as well as Ernst & Young LLP. Mr. Kelly holds a B.A. in psychology from the College of the Holy
Cross and an M.S./M.B.A. from Northeastern University. |
|
James R. Rusche
Senior Vice President, Research and Development
| James R. Rusche, Ph.D. joined Repligen in March 1996 as Vice President, Research and Development in
connection with Repligen’s merger with Glycan Pharmaceuticals, Inc. In 2001, Mr. Rusche became Senior Vice
President, Research and Development. From July 1994 to March 1996, Mr. Rusche was Vice President, Research
and Development of Glycan Pharmaceuticals, Inc. From February 1985 to June 1994, he held numerous research
positions at Repligen, most recently as Vice President, Discovery Research. Mr. Rusche holds a B.S. in
microbiology from the University of Wisconsin, LaCrosse and a Ph.D. in immunology from the University of
Florida. |
|
|
Daniel P. Witt
Senior Vice President, Global Operations
| Daniel P. Witt, Ph.D. joined Repligen in March 1996 as Vice President, Business Development in
connection with Repligen’s merger with Glycan Pharmaceuticals, Inc. In March 2012, Mr. Witt became Senior
Vice President, Global Operations. From April 2006 to February 2012, Mr. Witt was Vice President, Operations.From October 1993 to March 1996, Mr. Witt was Vice President, Business Development of Glycan
Pharmaceuticals, Inc. From April 1983 to September 1993, he held numerous research positions at Repligen,
most recently as Vice President, Technology Acquisition. Mr. Witt holds a B.A. in chemistry from Gettysburg
College and a Ph.D. in biochemistry from the University of Vermont. |
|
Howard Benjamin
Vice President, Business Development
| Howard Benjamin, Ph.D. has served as Vice President, Business Development since joining the Company in
January 2009. Previously Mr. Benjamin worked at translational medicine start-ups Leap Technology from March
2007 to December 2008 and Growth Point Sciences from August 2005 to December 2006 in various roles
including Vice President, Research and Development. From January 2000 to August 2005, Mr. Benjamin was
Vice President, Corporate Development at Daiichi Asubio Medical Research Laboratories and from 1994 to
2000, Mr. Benjamin was Vice President, Discovery Research at Praecis Pharmaceuticals. Mr. Benjamin holds an
S.B. in Biology from M.I.T. and a Ph.D. in Molecular Biology from University of California, Berkeley. |
|
|
Stephen Tingley
Vice President, Bioprocessing Sales and Marketing
|
|
|
Board of Directors
|
|
Glenn L. Cooper
Glenn L. Cooper, M.D. has served as a Director of Repligen since August 2009. Mr. Cooper served as
Executive Chairman of Coronado BioSciences, Inc. from 2010 to 2012. Prior to that, Mr. Cooper served as the
Chairman and Chief Executive Officer of Indevus Pharmaceuticals, Inc., a specialty pharmaceutical company
focused on urology and endocrinology, from 2000 to 2009 and as Chief Executive Officer and Director from
1993 to 2000. Prior to joining Indevus in 1993, Mr. Cooper held numerous executive level positions including
President and Chief Executive Officer of Progenitor, Inc., Executive Vice President and Chief Operating Officer
of Sphinx Pharmaceuticals Corporation, and various clinical and regulatory positions with Eli Lilly and
Company. Mr. Cooper has participated in the development, approval and commercialization of numerous drugs
including Prozac®, Axid®, Lorabid®, Ceclor®, SANCTURA®, SANCTURA XR®, Supprelin-LA® and Vantas®.
Mr. Cooper received an M.D. from Tufts University School of Medicine, performed his postdoctoral training in
Internal Medicine and Infectious Diseases at the New England Deaconess Hospital and the Massachusetts
General Hospital and received a B.A. from Harvard College. Mr. Cooper also serves as a Director of Gentium
SpA and is the Chairman of the Board of Directors of Lascaux Media, LLC, a privately held company.
Mr. Cooper’s qualifications to sit on the Board of Directors of the Company include his leadership roles at
pharmaceutical companies and his expertise in the clinical and regulatory areas.
|
|
Karen A. Dawes
Chairman
| Karen A. Dawes, Chairperson of the Board effective December 2011 and Co-Chairperson of the Board from
July 2011 to December 2011, has served as a Director of Repligen since September 2005. She is currently
President of Knowledgeable Decisions, LLC, a management consulting firm. Ms. Dawes served from 1999 to
2003 as Senior Vice President and U.S. Business Group Head for Bayer Corporation’s U.S. Pharmaceuticals
Group. Prior to joining Bayer, she was Senior Vice President, Global Strategic Marketing, at Wyeth, a
pharmaceutical company (formerly known as American Home Products), where she held responsibility for
worldwide strategic marketing. Ms. Dawes also served as Vice President, Commercial Operations for Genetics
Institute, Inc., which was acquired by Wyeth in January 1997, designing and implementing that company’s initial
commercialization strategy to launch BeneFIX® and Neumega®. Ms. Dawes began her pharmaceuticals industry
career at Pfizer, Inc. where, from 1984 to 1994, she held a number of positions in Marketing, serving most
recently as Vice President, Marketing of the Pratt Division. At Pfizer, she directed launches of Glucotrol®/
Glucotrol XL®, Zoloft®, and Cardura®. Ms. Dawes also serves as a Director of Depomed, Inc., Inspiration
Biopharmaceuticals, Inc. and Seaside Therapeutics LLC. Ms. Dawes’ qualifications to sit on the Company’s
Board of Directors include her extensive experience in both a managerial and consulting capacity with
pharmaceutical companies as well as her considerable marketing background. Ms. Dawes received a B.A. and
M.A. in English from Simmons College and an M.B.A. from Harvard Business School. |
|
|
Alfred L. Goldberg
| Alfred L. Goldberg, Ph.D. has served as a Director of Repligen since July 2008. Mr. Goldberg is currently a
Professor of Cell Biology at Harvard Medical School. Mr. Goldberg has been associated with Harvard University
during his entire academic career. He was appointed an Assistant Professor of Physiology at Harvard Medical School in 1969 and has been a full professor since 1977. Mr. Goldberg has served as a consultant to many
biotechnology and pharmaceutical companies and served on Scientific Advisory Boards of numerous foundations
and biotechnology companies (including Biogen, ArQule, Elan and ProScript). Mr. Goldberg earned an A.B.
from Harvard College in 1963, was a Churchill Scholar at Cambridge University and after studying at Harvard
Medical School, earned his Ph.D. from Harvard University in 1968. He is internationally recognized for his
multiple discoveries relating to protein degradation in cells and especially relating to the physiological functions
and mechanisms of the ubiquitin-proteasome pathway. These discoveries provided the basis for the development
of proteasome inhibitors which are widely used in cancer treatment. Mr. Goldberg is a member of the Institute of
Medicine of the National Academy of Sciences and American Academy of Arts and Sciences. The Board of
Directors believes Mr. Goldberg’s qualifications to sit on the Board of Directors include the insight he has
gleaned as a consultant in the biotechnology and pharmaceutical fields as well as the significant contributions he has made to academia. |
|
Michael A. Griffith
| Michael A. Griffith has served as a Director of Repligen since April 2012. Mr. Griffith is currently the Chief
Executive Officer and a director at Laureate Biopharma, a full-service contract manufacturing organization
focused on the production and manufacture of biologic drugs. Prior to joining Laureate in April 2010, he was on
the board of directors at Centrue Financial Corporation and its commercial banking subsidiary, Centrue Bank
(NASDAQ: TRUE), from 2002 to March 2010. Mr. Griffith was the founder of Aptuit, Inc., a global contract
pharmaceutical research, development and manufacturing company, and from 2004 to 2008 served as the
company’s CEO. From 1996 to 2000, Mr. Griffith was with ChiRex, Inc. (NASDAQ: CHRX), where he initially
served as CFO before being named the company’s Chairman and CEO. Mr. Griffith was part of the team that led
the initial public offering for ChiRex, which was later sold for $600 million to Rhodia SA, a NYSE-listed, Parisbased
specialty chemicals company. Prior to his involvement in the biopharmaceutical industry, Mr. Griffith
worked for nearly 15 years as a commercial and investment banker at Credit Suisse, First Boston and Bankers
Trust Company. He earned a Masters of Management from the Kellogg Graduate School of Management at
Northwestern University, and a B.S. in business administration from the University of Kansas. The Board of
Directors believes Mr. Griffith’s qualifications to sit on the Board of Directors include his extensive experience
in the areas of pharmaceutical development and manufacturing and his financial experience. |
|
|
Earl Webb Henry
| Earl Webb Henry, M.D. has served as a Director of Repligen since December 2007. Mr. Henry is currently
an independent consultant. From March 2009 to June 2011, Mr. Henry was Chief Medical Officer for inVentiv
Clinical Solutions. From 2004 to 2009, Mr. Henry was Senior Vice President, Medical Affairs for inVentiv
Clinical Solutions. From 2001 to 2004, Mr. Henry served as the Medical Director for HHI Clinical Research and
Statistical Services, LLC until it was acquired by inVentiv Health, Inc. in 2004. Other positions held by
Mr. Henry include Senior Vice President and Head, Worldwide Clinical Research and Regulatory Affairs for
Cephalon, Inc., Vice President, Clinical Research for Guilford Pharmaceuticals Inc., Global Head of Central
Nervous System Therapeutic Area for Sandoz Research Institute, and Senior Associate Director of Clinical
Research for Pfizer Central Research. Mr. Henry holds a B.S. in Chemistry from the University of Illinois and an
M.D. from the University of Chicago and completed his residency and fellowship at Harvard Medical School in
neurology and neuropathology. The Board of Directors believes Mr. Henry’s qualifications to sit on the Board of
Directors include his years of executive, research and regulatory experience in the life sciences industry. |
|
Walter C. Herlihy
| Walter C. Herlihy, Ph.D. joined Repligen in March 1996 as President, Chief Executive Officer and Director
in connection with Repligen’s merger with Glycan Pharmaceuticals, Inc. From July 1993 to March 1996,
Mr. Herlihy was the President and CEO of Glycan Pharmaceuticals, Inc. From October 1981 to June 1993, he
held numerous research positions at Repligen, most recently as Senior Vice President, Research and
Development. Mr. Herlihy holds an A.B. in chemistry from Cornell University and a Ph.D. in chemistry from
MIT. The Board of Directors believes Mr. Herlihy’s qualifications to sit on the Board of Directors include his
decades of experience in the pharmaceutical field, including over 15 years as President and Chief Executive
Officer of the Company, and his deep understanding of the Company’s historical and current business strategies,
objectives and products. |
|
|
Alexander Rich
| Alexander Rich, M.D. is a Co-Founder of Repligen, served as a Director of Repligen from May 1981 to May 2012
and currently serves as Chairman Emeritus of the Board. Mr. Rich has been on the faculty of MIT since 1958 and is the
Sedgwick Professor of Biophysics. Internationally recognized for his contributions to the molecular biology of nucleic
acids, he has determined their three-dimensional structure and has investigated their activity in biological systems. He
is widely known for his work in elucidating the three-dimensional structure of transfer RNA, which is a component of
the protein synthesizing mechanism, and for his discovery of a novel, left-handed form of DNA. He is a member of the
National Academy of Sciences, the American Philosophical Society, the Pontifical Academy of Sciences, Rome, and a
foreign member of the French Academy of Sciences, Paris.Mr. Rich also serves as a Director of Profectus
Biosciences, Inc., a privately held biotechnology company. The Board of Directors believes Dr. Rich’s qualifications to
serve as Chairman Emeritus of the Board include his significant accomplishments to the field of life sciences, both in
his business endeavors and in his academic contributions. |
|
Thomas F. Ryan Jr.
| Thomas F. Ryan Jr. has served as a Director of Repligen since September 2003 and is currently a private
investor. Mr. Ryan served as the President and Chief Operating Officer of the American Stock Exchange from
October 1995 to April 1999. Prior to 1995, he held a variety of positions at the investment banking firm of
Kidder, Peabody & Co., Inc., serving as the firm’s Chairman in 1995. He holds a bachelor’s degree from Boston
College and is a graduate of the Boston Latin School. Mr. Ryan is a Director for the New York State Independent
System Operator, a Director for BNY Mellon Asset Management Mutual Funds Board. Mr. Ryan’s qualifications
to sit on the Company’s Board of Directors include his years of experience in the areas of securities trading and
investment banking. |
|
|
